Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Combination therapeutic mode is likely to be the key to enhance the efficacy of immunotherapy in a wider range of cancer patients. Herein, we conducted an open-label, single-arm, multicenter, phase II clinical trial that enrolled patients with advanced solid tumors who had progressed after standard treatments. Methods: for intolerable cases) was intravenously (IV) administered once within 48 hours after radiotherapy. Then, camrelizumab (200mg IV, q3w) and anti-angiogenic drugs were given regularly until disease progression. The primary endpoint was objective response rate (ORR) in the target lesions evaluated by investigators per RECIST 1.1. The secondary endpoints were disease control rate (DCR) and treatment-related adverse events (TRAEs). Results: Between November 2020 and June 2022, 60 patients were enrolled. The median follow-up was 9.0 months (95% confidence interval (CI) 5.5-12.5). Of 52 evaluable patients, the overall ORR and DCR were 34.6% and 82.7%, respectively. Fifty patients with target lesions were evaluable, the ORR and DCR of the target lesions were 35.3% and 82.4%, respectively. The median progression-free survival was 5.3 months (95% CI 3.6, 6.2), and the median overall survival was not reached. TRAEs (all grades) occurred in 55 (91.7%) patients. The most common grade 3-4 TRAEs were lymphopenia (31.7%), anemia (10.0%), and leukopenia (10.0%). Conclusion: The combination of radiotherapy, liposomal irinotecan, camrelizumab, and anti-angiogenesis therapy demonstrated promising anti-tumor activity and well tolerance in various advanced solid tumors. Clinical trial registration: https://clinicaltrials.gov/ct2/home, identifier NCT04569916.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
- Date Crossref
- 28/03/2023
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nanjing Drum Tower Hospital pays non établi dans la noticeÉtablissement de santé
-
Jiangsu University Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Affiliated Hospital of Jiangsu University pays non établi dans la noticeÉtablissement de santé
-
Xuzhou Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Second People’s Hospital of Huai’an Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
Jiangsu Hengrui Medicine (China) pays non établi dans la noticeEntreprise
-
Nanjing Jiangning Hospital pays non établi dans la noticeÉtablissement de santé
-
Medical School of Nanjing University The Comprehensive Cancer Center of Drum Tower Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Research and Development pays non établi dans la noticeÉtablissement de santé
-
Nanjing Jiangbei Hospital Department-II of General Surgery pays non établi dans la noticeÉtablissement de santé
Nanjing Drum Tower Hospital, Department of Oncology — Jiangsu University et Affiliated Hospital of Jiangsu University, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.